1094例晚期乳腺癌患者骨转移的治疗与模式——德国乳腺癌肿瘤登记前瞻性队列研究结果
德国乳腺癌肿瘤登记(TMK)前瞻性多中心队列研究2007年起在140家中心开展,本次 interim 分析纳入1094例骨转移患者。89%(n=976)接受骨靶向药物治疗,2014-2015年37%用唑来膦酸、36%用地舒单抗,中位治疗20个月。一线治疗开始时仅骨转移、非内脏±骨转移、内脏±骨转移患者中位总生存分别为54、38、28个月。
要点
- 89%(n=976)骨转移患者接受骨靶向药物治疗,2014-2015年唑来膦酸37%、地舒单抗36%。
- 骨靶向药物中位治疗20个月,骨转移诊断后中位3周开始,死亡前中位7周结束。
- 一线治疗时仅骨转移者中位总生存54个月,非内脏±骨转移38个月,内脏±骨转移28个月。
核心结论
- 骨靶向药物的选择与疗程与德国适用指南一致。
- 据作者所知,这是首次展示常规实践中骨转移患者的发生率、转移模式、治疗和生存数据。
研究设计与样本
- 正在进行的、前瞻性、多中心、基于人群的队列研究——德国乳腺癌肿瘤登记(TMK),2007年启动,覆盖德国140家中心。
- 本次 interim 分析纳入1094例骨转移的晚期乳腺癌患者,由德国诊所肿瘤医生治疗。
主要发现
- 一线治疗开始时,激素受体阳性患者中36%为仅骨转移,激素受体阴性患者中仅20%为仅骨转移。
- 89%(n=976)的骨转移患者接受了骨靶向药物治疗。
- 2014-2015年,37%的患者接受双膦酸盐唑来膦酸,36%接受抗体地舒单抗。
- 骨靶向药物中位治疗时长20个月(四分位距31.5个月),骨转移诊断后中位3周开始,死亡前中位7周结束。
- 一线治疗开始时中位总生存因转移类型而异:仅骨转移54个月(95%CI 37.6-70.8),非内脏伴或不伴骨转移38个月(95%CI 29.4-44.2),内脏伴或不伴骨转移28个月(95%CI 24.2-31.0)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A high proportion of patients with breast cancer develop bone metastases, yet data on routine treatment with bone-targeted agents (BTA) are rare. We report real-life outcome data of patients with breast cancer metastasised to the bone treated by office-based oncologists in Germany. The ongoing, prospective, multicentre, population-based cohort study Tumour Registry Breast Cancer (TMK) was started in 2007 in 140 centres across Germany. This interim analysis of 1094 patients with bone metastases revealed differences among the tumour subtypes: at start of first-line therapy, 36% of the patients with hormone receptor (HR)-positive and only 20% of the patients with HR-negative tumours presented with bone-only metastasis. The majority of patients with bone metastases (89%, n = 976) received BTA therapy. In 2014-2015, 37% of the patients received the bisphosphonate zoledronic acid and 36% the antibody denosumab. Median duration of BTA therapy was 20 months (interquartile range 31.5 months), starting a median of 3 weeks after diagnosis of bone metastases, and ending a median of 7 weeks before death. The median overall survival (OS) also varied among the types of metastasis at start of first-line therapy ranging from 54 months (95% confidence interval [CI] 37.6-70.8), 38 months (95% CI 29.4-44.2) to 28 months (95% CI 24.2-31.0) for patients with bone-only metastases, non-visceral with or without bone metastases and visceral with or without bone metastases respectively. We show that choice and duration of BTA therapies are in conformity with guidelines applicable in Germany. To our knowledge, this is the first presentation of data on incidence, metastatic pattern, treatment and survival of patients with bone metastases in routine practice.
引用
- Schröder J, Fietz T, Köhler A, et al. Treatment and pattern of bone metastases in 1094 patients with advanced breast cancer - Results from the prospective German Tumour Registry Breast Cancer cohort study. Eur J Cancer. 2017. PMID: 28494404. doi:10.1016/j.ejca.2017.03.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。